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Regulation of gene expression in mammalian mitochondria by microRNAs is reported by Zhang
et al. During muscle cell differentiation, localization of a miRNA is increased within mitochondria,
where it interacts with Ago2 to selectively activate translation ofmtDNA-encodedmRNAs. The find-
ings represent a new mitochondrial regulatory pathway and a potentially powerful means to pur-
posefully manipulate mtDNA expression.Mitochondrial DNA (mtDNA) is essential in
mammals, encoding thirteen proteins that
are subunits of the ATP-producing oxida-
tive phosphorylation (OXPHOS) com-
plexes. After transcription and process-
ing, mitochondrial mRNAs are translated
by a dedicated set of ribosomes (distinct
from cytoplasmic ribosomes) utilizing
rRNAs and tRNAs that are also encoded
by mtDNA (Bestwick and Shadel, 2013).
With the exception of TACO, a transla-
tional regulator of the COX1 mRNA (Wer-
aarpachai et al., 2009), evidence for
translational regulation of mitochondrial
mRNAs in mammals is sparse. The study
by Fu and colleagues in this issue of
Cell (Zhang et al., 2014) has broken
exciting new ground in this area by
showing that microRNAs function in the
mitochondrial matrix to upregulate trans-
lation of mtDNA-encoded mRNAs (Fig-
ure 1) and that this regulation occurs
during muscle cell differentiation.
MicroRNAs are short noncoding RNAs
that associate with the Argonaute-con-
taining RISC complexes to target specific
cytoplasmic mRNAs for degradation or
translational repression. In addition to
this common form of negative posttran-
scriptional regulation, microRNAs have
been suggested to augment translation
under specific circumstances (Vasude-
van, 2012). While the mechanism of this
positive regulation is less clear, the lack
of a CAP onmRNAs and Argonaute acting
independently of its binding partners of
the GW182 family have been suggested
as critical (Vasudevan, 2012). A specific
characteristic of mitochondrial mRNAs is
that they are not capped, thus fulfillingone criterion for positive regulation. In
the current study, Zhang et al. show that
while Argonaute 2 (Ago2) is in the mito-
chondrial matrix, none of the GW182 pro-
teins localize to mitochondria (Figure 1).
Thus, it appears that a unique biological
context has arisen to allow upregulation
of mitochondrial translation by Ago2 and
microRNAs targeting specific mtDNA-
encoded mRNAs.
Zhang et al. are not the first to show
mitochondrial association of microRNAs
and to speculate that they exert direct
effects in mitochondria (Bandiera et al.,
2013), and there is one report of a
microRNA negatively regulating mito-
chondrial COX1 expression in heart mito-
chondria (Das et al., 2012). However,
Zhang et al. use a battery of biochemical
and cytological assays to clearly demon-
strate matrix localization of a specific
microRNA, miR-1, and of Ago2, and they
provide extensive and compelling evi-
dence that miR-1 binds directly to the
mitochondrial ND1 and COX1 mRNAs
along with Ago2 to enhance their transla-
tion. The authors also find that at least two
other mitochondrial-localized microRNAs
act similarly.
Since microRNAs are primarily known
for their actions on nucleus-encoded
mRNAs in the cytoplasm, one question
that arises is how microRNAs get into
mitochondria in the first place? In fact, it
has long been appreciated that RNA mol-
ecules are imported into mitochondria.
For example, in some organisms the
tRNAs for mitochondrial translation are
all imported (Tarassov et al., 2007). In
mammals, there are at least two majorCellRNPs (RNase P and RNase MRP) in mito-
chondria (Shadel and Clayton, 1997) that
require import of a relatively large RNA
subunit into the matrix for assembly and
activity. This requires a specific RNA
import mechanism and targeting signals
in the RNA (Wang et al., 2010). Whether
microRNAs enter mitochondria by this
mechanism or another parallel pathway
and if this is regulated will be important
to decipher.
The entry point for the study by Zhang
et al. was their observation that mtDNA-
encoded proteins were uniquely upregu-
lated in muscle and in differentiating
mouse C2C12 cells in a manner that
does not involve an increase in mtDNA
or mitochondrial transcripts. In the end,
they showed that the increase in ND1
and COX1 protein was driven, at least in
part, by increased miR-1 in mitochondria
targeting these RNAs for enhanced trans-
lation in conjunction with Ago2. While the
precise requirement for this new form of
regulation in muscle differentiation was
not ultimately revealed in the study, it
begs the question of what role microRNA
regulation of mitochondrial translation
plays in vivo. While many scenarios can
be envisioned, one interesting possibility
is that partitioning of the relative amounts
of certain microRNAs in the cytoplasm
and mitochondria regulates their activity
on specific targets to coordinate mito-
chondrial activities with other cellular
functions. In this regard, the observation
by Zhang et al. that miR-1 simultaneously
represses cytoplasmic targets and acti-
vates mitochondrial mRNAs is intriguing
(Figure 1). One potential manifestation of158, July 31, 2014 ª2014 Elsevier Inc. 477
Figure 1. Cytoplasmic-Mitochondrial MicroRNA Dynamics
A subset of microRNAs (e.g., miR-1 and others in the Zhang et al. study) is located both in the cytoplasm
and the mitochondrial matrix where they bind separate targets and mediate different outcomes. In the
cytoplasm, microRNAs bind their mRNA targets along with RISC complexes containing Ago2 (pink oval)
and a GW182 family protein (yellow oval) to repress translation. MicroRNAs that enter mitochondria, by a
yet-to-be defined import system (peach), associate with mtDNA-encoded mRNAs along with Ago2 that is
presumably imported through the normal protein import complexes (purple). Because GW182 family
proteins are not imported intomitochondria (red X) andmtDNA-encodedmRNAs are not capped (circle on
the cytoplasmic mRNA denotes a CAP), the mitochondrial Ago2-microRNA complexes stimulate, rather
than repress, translation. This form of regulation likely leads to unique alterations in OXPHOS complex
assembly and activity to tailor mitochondrial function to specific cell types and physiological cues.this type of regulation might be to modu-
late the OXPHOS system to accommo-
date specific cellular demands. For
example, if a microRNA targeted both a
nuclear- and mtDNA-encoded subunits
of the same OXPHOX complex, increased
import into mitochondria and depletion in
the cytoplasm might simultaneously in-
crease translation in both compartments.
This may be a means to enhance or coor-
dinate complex assembly by controlling
the relative expression of nuclear and
mtDNA-encoded subunits to remodel
the amount or activity of specific
OXPHOS complexes. During processes
like cell growth and differentiation (e.g.,
muscle differentiation) that have unique
energy requirements or rely on specific478 Cell 158, July 31, 2014 ª2014 Elsevier Inmitochondria-generated signals like reac-
tive oxygen species, such control mecha-
nisms may be critical.
The identification of a functional
microRNA pathway in mitochondria
poses important questions for how mito-
chondrial gene expression is controlled
in vivo, adding a new form of positive
translational regulation to the list of possi-
bilities. The findings also open the door
to asking important basic questions
about how assembly of the OXPHOS sys-
tem is controlled by providing an ex-
perimental means to perturb mtDNA
expression in specific ways in cell
models and perhaps inmice (e.g., through
microRNA mimics that would specifically
target one mtDNA-encoded subunit).c.Finally, many mitochondrial diseases are
caused by defects in mitochondrial trans-
lation (Pearce et al., 2013). Thus, the abil-
ity to upregulate mitochondrial translation
using a microRNA-based strategy may be
a new therapeutic route for these severe
diseases which currently have no cure
and few treatment options.
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